Tyrosine kinase LYN is an oncotarget in human cervical cancer: A quantitative proteomic based study
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1746 views | HTML 2347 views | ?
Shuaibin Liu1, Xiaoming Hao1, Xiaolan Ouyang1, Xiaojing Dong1, Yixuan Yang2, Tinghe Yu1, Jianguo Hu1, Lina Hu1
1Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China
2Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China
Li-Na Hu, email: [email protected]
Keywords: iTRAQ, cervical cancer, LYN, STAT3, IL-6
Received: March 28, 2016 Accepted: September 02, 2016 Published: September 26, 2016
Cervical cancer is one of the most common malignant tumor in women. The mechanisms of cervical cancer are intricate and have not been fully understood. Therefore, we employed iTRAQ to obtain novel proteins profile which participates in the tumor oncogenesis of cervical cancer. 3300 proteins were identified aberrantly expressed in cervical cancer, and western bolt was performed to validate the results of iTRAQ. Then, we selected LYN for further study. Immunohistochemistry identified that LYN expression was significantly increased in cervical cancer tissues than that in cancer adjacent normal cervical tissues and normal cervical tissues. The increased LYN expression was significantly correlated with cancer differentiation and FIGO stage. Silencing LYN inhibited cell proliferation, migration and invasion, conversely, overexpression LYN promoted cell proliferation, migration and invasion. In terms of mechanism, LYN could also promote cervical cancer cells metastasis through activating IL-6/STAT3 pathway. In vivo study, overexpression LYN promoted tumor growth, meanwhile knockdown LYN inhibited tumor growth. These results indicate that LYN tyrosine kinase is an oncogenic gene and can serve as a novel target for cervical cancer research and therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.